Prevention of Cardiovascular Disease in Women
- PMID: 29744010
- PMCID: PMC5935277
- DOI: 10.14797/mdcj-13-4-185
Prevention of Cardiovascular Disease in Women
Abstract
Cardiovascular diseases are the leading cause of morbidity and mortality among women worldwide. The pathophysiological basis of cardiovascular health among men and women is not identical. This leads to variable cardiovascular responses to stimulus and presentation of cardiovascular disease symptoms, both of which can have a direct effect on treatment outcomes. Traditionally, the enrollment of women in clinical trials has been minimal, resulting in a lack of gender-specific analysis of clinical trial data and, therefore, the absence of concrete risk factor assessment among women. However, scientific progress in the past decade has identified a spectrum of risk factors for cardiovascular diseases that may be specific to women. These risk factors, which may include menopause, hypertensive disease of pregnancy, and depression, confer additional risk in women besides the traditional risk factors. The current state of knowledge and awareness about these risk factors is suboptimal at this time. Therefore, although the treatment of cardiovascular diseases is similar in both genders, appropriate risk stratification may be limited in women compared to men. The purpose of this review is to describe the recent trends in identifying female-specific risk factors for cardiovascular diseases, their utility in risk stratification, and current pharmacological options for women with regard to cardiovascular disease prevention.
Keywords: cardiovascular disease; cardiovascular risk factors; postmenopausal CVD; women and CVD.
Conflict of interest statement
Conflict of Interest Disclosure: Dr. Nambi receives research funding from Merck through Baylor College of Medicine, served on a regional advisory board for Sanofi-Regeneron, received an honorarium from Siemens Healthcare Diagnostics, and holds a provisional patent entitled “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche.
References
-
- von Mering GO, Arant CB, Wessel TR, . et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004. February 17; 109 6: 722– 5. - PubMed
-
- Hochman JS, Tamis JE, Thompson TD, . et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999. July 22; 341 4: 226– 32. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
